ArticleJournal of experimental & clinical cancer research : CR2019
Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.
Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- CRIP1 functions as an oncogene in acute myeloid leukemia by modulating glycolytic metabolic reprogramming.Scientific reports · 2026Article
- Probiotic Lactobacillus casei Inhibits Oral Squamous Cell Carcinoma Growth and Induces Apoptosis In Vitro.International dental journal · 2026Article
- CRIP1 promotes docetaxel resistance and immune-associated cell death modulation in prostate cancer.Frontiers in pharmacology · 2026Article
- Single-cell hdWGCNA identifies ICI-related-colitis key CD8 + T cells linked to immunotherapy response and prognosis in colon cancer.Discover oncology · 2025Article
- Article
- Cysteine-rich intestinal protein family: structural overview, functional diversity, and roles in human disease.Cell death discovery · 2025Review
- Article
- CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.EBioMedicine · 2024Article
- Article
- Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts.Cell death & disease · 2023Article
- CRIP1 Reshapes the Gastric Cancer Microenvironment to Facilitate Development of Lymphatic Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Unraveling the activation process and core driver genes of HSCs during cirrhosis by single-cell transcriptome.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- CRP‑1 promotes the malignant behavior of hepatocellular carcinoma cells via activating epithelial‑mesenchymal transition and Wnt/β‑catenin signaling.Experimental and therapeutic medicine · 2023Article
- Sirt3 restricts tumor initiation via promoting LONP1 deacetylation and K63 ubiquitination.Journal of translational medicine · 2023Article
- Subclones of bone marrow CD34Cancer · 2022Article
- CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma.The EMBO journal · 2022Article
- Article
- Modulation of tissue resident memory T cells by glucocorticoids after acute cellular rejection in lung transplantation.The Journal of experimental medicine · 2022Article
- Anti-Tumor Effects of Heat-KilledMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCysteine-rich intestinal protein 1 (CRIP1) is highly expressed in human intestine and aberrantly expressed in several types of tumor. However, studies on CRIP1 are limited and its role on tumor development and progression remains controversial and elusive.
methodsImmunohistochemistry was performed to evaluate the expression of CRIP1 in paired normal and colorectal tumor specimens, as well as colorectal cell lines. Functional assays, such as CCK8, TUNEL assay and in vivo tumor growth assay, were used to detect the proliferation, apoptosis and response to 5-FU of CRIP1. Western blot was used to analyze Fas-mediated pathway induced by CRIP1. Rescue experiments were performed to evaluate the essential role of CRIP1 for Fas-mediated apoptosis.
resultsWe demonstrated that CRIP1 is overexpressed in CRC tissues compared with adjacent normal mucosa. CRIP1 could dramatically recover the 5-Fluorouracil (5-FU) inhibited CRC cell proliferation in vitro and stimulate the tumor formation of CRC in vivo, probably through inhibiting CRC cell apoptosis. Moreover, CRIP1 also dramatically recovered the 5-Fluorouracil (5-FU) induced tumor cell apoptosis in vitro. Further study demonstrated that CRIP1 down-regulated the expression of Fas protein and proteins related to Fas-mediated apoptosis. CRIP1 could interact with Fas protein and stimulate its ubiquitination and degradation. In addition, a negative correlation was detected between the expression of CRIP1 and Fas protein in most of the clinical human CRC samples.
conclusionThe current research reveals a vital role of CRIP1 in CRC progression, which provide a novel target for clinical drug resistance of colorectal cancer and undoubtedly contributing to the therapeutic strategies in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.